No Data
No Data
Mural Oncology | 10-Q: Quarterly report
Express News | Mural Oncology PLC Qtrly Shr Loss $1.84
Mural Oncology 1Q Research and Development Expenses $26.9M >MURA
Mural Oncology 1Q Research and Development Expenses $26.9M >MURA
Express News | Mural Oncology PLC: Reiterates Cash Runway Projection Into 4Q 2025, With Sufficient Capital to Fund Key Clinical Readouts
Express News | Mural Oncology Announces First Quarter 2024 Financial Results and Provides Business Update
Mural Oncology Announces Upcoming Presentation at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
WALTHAM, Mass. and DUBLIN, Ireland, April 24, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (NASDAQ:MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed
No Data